Most previous studies have focused on pre-treatment inflammatory markers such as NLR, PLR, or C-reactive protein (CRP), showing consistent associations with poor prognosis in ovarian cancer [11,13,14]. The gene discussed is CRP; the disease is ovarian carcinoma.